MedPath

Effect of Probiotics on Lipid Management

Not Applicable
Conditions
Primary Hypercholesterolemia
Interventions
Other: Placebo controls
Dietary Supplement: Lactobacillus paracasei dietary supplement
Registration Number
NCT03952169
Lead Sponsor
Sun Yat-sen University
Brief Summary

Dysbiosis of gut microbiota has been reported to be involved in the development of hypercholesterolemia in both humans and animal models. Probiotics have been reported to have ameliorative effects in murine models. However, whether probiotics could help alleviate dyslipidemia in adults remain obscure.

Detailed Description

Probiotics are live microorganisms that have been associated with multiple health benefits. However, its protective role in adults has long been controversial. This study aims to examine the effect of 12-week probiotics supplementation on lipid management in Chinese adults. By understanding the mechanism by which probiotics exert the beneficial effects, we can better control the rising prevalence of hypercholesterolemia, which is a major risk factor for cardiovascular diseases.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Eligible subjects include men and women 18 to 75 years of age with primary hypercholesterolemia who has a total cholesterol level of 5.18 mmol/L or higher and/ or an LDL cholesterol level of 2.59 mmol/L or higher;
  • Absence of any diet, dietary supplement and medication that might interfere with lipid homoeostasis and gut microbiota, especially antibiotics and probiotics.
Exclusion Criteria
  • Triglyceride levels higher than 3.95 mmol/L, or any other systemic, metabolic and cardiovascular or cerebrovascular diseases;
  • Type 1 diabetes, type 2 diabetes treated with insulin or other medications;
  • Acute illness or current evidence of acute or chronic inflammatory or infective diseases;
  • Participation in any diet or lifestyle program more than 2 times per week in the latest 3 months prior to recruitment;
  • Mental illness rendering them unable to understand the nature, scope, and possible consequences of the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo groupPlacebo controlsParticipants will be given capsules containing microcrystalline cellulose once daily for 12 weeks followed by comprehensive physical and clinical examinations.
Probiotics groupLactobacillus paracasei dietary supplementParticipants will be given capsules containing Lactobacillus paracasei once daily for 12 weeks followed by comprehensive physical and clinical examinations.
Primary Outcome Measures
NameTimeMethod
Triglyceridebaseline, 4 weeks, 8 weeks and 12 weeks

changes of triglyceride levels in plasma by automatic biochemical analyzer

Total cholesterolbaseline, 4 weeks, 8 weeks and 12 weeks

changes of total cholesterol levels in plasma by automatic biochemical analyzer

LDL-cholesterolbaseline, 4 weeks, 8 weeks and 12 weeks

changes of LDL-cholesterol levels in plasma by automatic biochemical analyzer

gut microbiotabaseline, 4 week, 8 weeks and 12 weeks

changes of gut microbiota by metagenomics

non HDL-cholesterolbaseline, 4 weeks, 8 weeks and 12 weeks

changes of non HDL-cholesterol levels in plasma

Secondary Outcome Measures
NameTimeMethod
blood pressurebaseline, 4 week, 8 week and 12 weeks

changes of blood pressure

pulse wave velocitybaseline and after 12-week intervention

changes of pulse wave velocity by VP-1000plus from Omron

microbial metabolitebaseline and after 12-week intervention

changes of microbial metabolite by untargeted metabolomics

ankle Brachial Indexbaseline and after 12-week intervention

changes of ankle Brachial Index by VP-1000plus from Omron

Trial Locations

Locations (1)

Department of Nutrition and Food Hygiene

🇨🇳

Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath